TABLE 3.
Virulence of WT and mutant CHIKVs in the presence or absence of MAbs
| Virus | Treatmenta | Survival rate (%) | Mean survival time (days) | No. of mice |
|---|---|---|---|---|
| CHIKV WT | PBS | 0 | 3.8 ± 0.1 | 10 |
| CHIKV WT | CHK-152 + CHK-166 | 100 | >21 | 7 |
| CHIKV E1-K61T | PBS | 0 | 4.9 ± 0.1 | 9 |
| CHIKV E1-K61T | CHK-166 | 0 | 5.8 ± 0.3 | 9 |
| CHIKV E2-D59N | PBS | 0 | 4.9 ± 0.1 | 8 |
| CHIKV E2-D59N | CHK-152 | 0 | 5.4 + 0.2 | 9 |
| CHIKV E1-K61T E2-D59N | PBS | 0 | 5.4 ± 0.2 | 10 |
| CHIKV E1-K61T E2-D59N | CHK-152 + CHK-166 | 0 | 6.4 ± 0.3 | 10 |
a
Six to 8 week-old Ifnar1−/− mice were passively transferred PBS or 50 μg of CHK-166, CHK-152, or CHK-166 plus CHK-152 via an intraperitoneal injection 1 day before infection with 10 FFU of CHIKV WT, CHIKV E1-K61T, CHIKV E2-D59N, or CHIKV E1-K61T E2-D59N virus via a subcutaneous route.